Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Shots: Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseases As per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP)…

ByRidhi RastogiApril 7, 2025

NEWS

Luye Pharma Launches Erzofri in the US for Schizophrenia and Schizoaffective Disorder

Shots: Luye Pharma has launched Erzofri extended-release injectable suspension in the US to treat adults with schizophrenia & as monotx. or adjunct therapy for adults with schizoaffective disorder Erzofri was approved by the US FDA based on a multiple-dose, parallel-group study evaluating its PK profile & relative bioavailability at steady state vs reference product, demonstrating…

ByRidhi RastogiApril 7, 2025

NEWS

ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)

Shots: ABL Bio has entered into a global licensing agreement with GSK for its Grabody-B BBB shuttle platform to develop therapies targeting various novel pathways using antibodies, siRNA, & ASOs for neurodegenerative diseases As per the deal, GSK will handle preclinical & clinical activities, manufacturing, & marketing of the potential programs in exchange for ~$99.4M,…

ByRidhi RastogiApril 7, 2025

NEWS

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots: Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseases As per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience. Konrad believes…

BySaurabh ChaubeyApril 4, 2025

NEWS

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Shots: Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 deal As per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US…

ByRidhi RastogiApril 3, 2025

NEWS

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Shots: Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete…

ByRidhi RastogiApril 2, 2025

EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Vikram Mohan

Vikram Mohan will be joining the upcoming Pharma 2025 event as a panelist with the Topic “Content’s Industrial Revolution”. Vikram believes that with a paradigm shift from the traditional approach to creating, approving, reviewing, and deploying content in the evolving biopharma industry, there’s room for generative AI to act as an assistant to make the…

BySaurabh ChaubeyApril 2, 2025

NEWS

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

Shots: Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platform Furthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disorders Upon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and…

ByRidhi RastogiApril 1, 2025

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…

ByRidhi RastogiApril 1, 2025

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Luye Pharma Launches Erzofri in the US for Schizophrenia and Schizoaffective Disorder

ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Reuters Pharma 2025: Pre-Conference Talks Featuring Vikram Mohan

Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders

PharmaShots’ Key Highlights of First Quarter 2025

Contact US

FOLLOW US